Last 22 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.20 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.92 | 3.45 | 5.22 | 3.11 | 1.60 | 2.91 | 1.20 | 3.06 | 15.28 | 24.06 | 15.93 | 11.16 | 7.90 |
| — | +18.7% | +336.8% | +1.8% | -89.5% | -87.9% | -92.5% | -72.6% | +93.5% | +201.4% | -16.9% | +67.3% | -17.9% | |
| P/B Ratio | 0.74 | 0.91 | 1.45 | 1.01 | 0.48 | 0.71 | 0.53 | 0.82 | 2.35 | 3.05 | 2.82 | 2.39 | 1.59 |
| — | +27.3% | +171.5% | +22.1% | -79.7% | -76.7% | -81.1% | -65.5% | +48.2% | +68.7% | -20.2% | -2.8% | -60.5% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Ginkgo Bioworks Holdings, Inc.'s operating margin was -211.9% in Q4 2025, up 19.9 pp QoQ and up 24.4 pp YoY. The trailing four-quarter average of -190.0% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin expanded 59.4% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.5% | 124.4% | 67.0% | 70.1% | 75.1% | 78.1% | 88.8% | 75.6% | 75.7% | 81.0% | 87.5% | 77.5% | 72.3% |
| — | +59.4% | -24.5% | -7.2% | -0.9% | -3.6% | +1.5% | -2.5% | +4.8% | +16.9% | +39.2% | +38.9% | +46.7% | |
| Operating Margin | -185.3% | -211.9% | -231.8% | -132.1% | -184.1% | -236.3% | -62.0% | -396.7% | -469.1% | -512.5% | -516.7% | -228.6% | -267.3% |
| — | +10.3% | -273.9% | +66.7% | +60.7% | +53.9% | +88.0% | -73.5% | -75.5% | -114.8% | +47.6% | +49.0% | +33.3% | |
| Net Margin | -183.8% | -241.8% | -207.9% | -121.6% | -188.2% | -245.2% | -63.3% | -386.4% | -437.3% | -609.1% | -546.4% | -215.1% | -254.0% |
| — | +1.4% | -228.3% | +68.5% | +56.9% | +59.7% | +88.4% | -79.6% | -72.2% | -239.1% | +45.9% | +53.5% | +27.6% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -51.1% | -15.1% | -13.8% | -9.6% | -13.3% | -14.2% | -6.9% | -23.9% | -15.9% | -18.0% | -22.0% | -11.1% | -12.3% |
| — | -6.4% | -99.1% | +59.9% | +16.2% | +21.2% | +68.5% | -114.2% | -29.9% | -62.1% | +50.7% | +73.5% | +67.0% | |
| ROA | -25.0% | -7.0% | -6.7% | -4.8% | -6.8% | -7.5% | -3.6% | -13.5% | -10.2% | -11.5% | -14.0% | -7.4% | -8.3% |
| — | +7.0% | -83.8% | +64.7% | +33.4% | +34.4% | +74.1% | -84.0% | -23.6% | -43.2% | +59.5% | +77.7% | +71.1% | |
| ROIC | -34.3% | -6.5% | -7.9% | -6.1% | -9.6% | -12.4% | -7.0% | -35.8% | -34.7% | -26.7% | -30.3% | -17.1% | -19.4% |
| — | +47.7% | -12.8% | +82.9% | +72.3% | +53.5% | +76.9% | -109.5% | -78.7% | +19.4% | +86.5% | +93.1% | +96.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 12.5% YoY to 4.92x, tightening the short-term liquidity position. Debt/Equity has risen for 9 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.82 | 0.82 | 0.76 | 0.70 | 0.67 | 0.65 | 0.56 | 0.54 | 0.24 | 0.22 | 0.32 | 0.27 | 0.25 |
| — | +25.5% | +35.3% | +28.9% | +182.6% | +199.5% | +73.3% | +98.6% | -5.5% | -14.4% | +675.3% | +730.9% | +1385.6% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.92 | 4.92 | 4.39 | 5.41 | 4.88 | 5.62 | 5.79 | 4.71 | 5.34 | 6.11 | 6.78 | 7.49 | 6.92 |
| — | -12.5% | -24.2% | +14.7% | -8.6% | -8.1% | -14.6% | -37.1% | -22.8% | -27.1% | -42.1% | -36.7% | -35.4% | |
| Quick Ratio | 4.92 | 4.92 | 4.39 | 5.41 | 4.88 | 5.62 | 5.79 | 4.71 | 5.34 | 6.11 | 6.78 | 7.49 | 6.91 |
| — | -12.5% | -24.2% | +14.7% | -8.6% | -8.1% | -14.6% | -37.0% | -22.7% | -26.9% | -41.9% | -36.4% | -35.2% | |
| Interest Coverage | — | — | — | — | — | -1102.19 | — | — | — | -1915.24 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 22 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonGinkgo Bioworks Holdings, Inc.'s current P/E is -1.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Ginkgo Bioworks Holdings, Inc.'s current operating margin is -185.3%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Ginkgo Bioworks Holdings, Inc.'s business trajectory between earnings reports.